The right to be forgotten and workers’ health protection: a critical balancing act Authors: Elpidio Maria Garzillo, Maria Grazia Lourdes Monaco Published: 2026 ABSTRACT The recent introduction of the right to oncological oblivion in some European states raises critical issues. While designed to protect cancer survivors from discrimination, this right may compromise occupational health surveillance for workers exposed to carcinogenic hazards. This commentary raises questions for future policy and research. The concept of oncological oblivion Right to be forgotten [RTBF] (also termed Oncological oblivion in international literature) [1–3] is a legal right allowing people cured of cancer to avoid discrimination based on their previous illness. This concept protects cancer survivors by allowing them to withhold information about their medical history when applying for mortgages, loans, insurance policies or jobs. This helps them to avoid the restrictions that are often imposed on individuals with a history of serious illness. These are some reflections as food for thought on the importance of balancing the omission of information to employers with the need to share past medical history confidentially with the occupational physician, to ensure these workers are protected in the workplace, which is necessary in the context of exposure to carcinogenic, mutagenic and reprotoxic agents, leaving open questions. In Europe, RTBF is an issue of increasing attention, to protect people cured of cancer and facilitate their reintegration into society without discrimination. The European Union’s Mission on Cancer (Horizon Europe, 2021–2027) includes the creation of a Europe-wide regulatory framework for uniform cancer protection to eliminate inequalities and stigma across Member States. This Mission accelerates progress in cancer prevention, diagnosis, and treatment, improves the quality of life for patients and survivors, and links workplace non-discrimination to the Plan’s objectives of inclusion and quality of life [4]. RTBF for cancer survivors has emerged across Europe through disparate national legislation, with notable variations in time limits, scope and explicit connections to employment and occupational health [1, 5, 6]. This primarily concerns consumer credit, insurance, financial services and loans [7]. Furthermore, in several European countries, including Italy, there are various provisions designed to ensure comprehensive protection for workers who have survived cancer. Indeed, in some cases, depending on the type of cancer and age of diagnosis, the right is accrued very quickly, in as little as a year after the end of treatment, such as for colon, breast, and thyroid cancers [8]. The Italian context Current Italian legislation, within the framework of occupational health and safety, provides for a system of health surveillance that includes a pre-employment medical examination prior to exposure to workplace risks [9, 10], as well as follow-up examinations. Under the current regulatory framework [11], a worker exercising the RTBF might omit to disclose their cancer history during the mandatory examination by the occupational physician. However, it is essential that the worker understands that, in the medical context, and specifically in the case of the occupational health examination, it has always been centred on confidentiality, even before the GDPR took effect [12]: employers cannot access diagnoses or medical histories, which remain the responsibility of the occupational health physician and are protected by professional privacy. On the other hand, a lack of information for the occupational health physician, who is responsible for assessing the worker’s fitness for work in hazardous environments (including exposure to carcinogens), could be an obstacle to the full protection of the worker’s health and safety. The role of occupational carcinogens: a potential health paradox Occupational exposure to carcinogens remains a significant public health burden. The International Agency for Research on Cancer (IARC) Monograph 2020 identifies multiple Group 1 carcinogens (definite human carcinogens), such as asbestos, benzene, silica dust, diesel exhaust, ionising radiation, and Group 2 A (defined as probably carcinogenic to humans), such as acrylamide, dichloromethane, and night shift work [13–15]. Cancer survivors are at an increased risk of developing a second primary malignancy as a result of occupational exposure to chemicals or radiation. This is because some cancer survivors have a genetic predisposition to the development of various cancers and because, in some cases, treatment-related organ toxicity (e.g. cardiac, pulmonary or renal) can make them more susceptible to carcinogens [16, 17]. These aspects are even more relevant when cancer survivors are exposed to multiple carcinogens, as in the case, for example, of simultaneous exposure to ionising radiation and night work in the healthcare sector [18]. Defining a worker’s vulnerability, particularly to recognised occupational carcinogens, is a key aspect of the occupational physician’s assessment process. A comprehensive process is required to assess the fitness of individuals with a history of cancer to work in a given occupation. This must take into account factors relating to the disease itself, the individual’s condition and their working environment. The process should also establish whether the disease had an occupational cause [19]. Under all conditions of exposure to carcinogens and mutagens (but also to reprotoxic substances for those who have undergone intensive cancer treatment), will the lack of information on past cancer history available to the occupational physician compromise the health of these workers? Balancing oblivion with occupational health protection International studies estimate that survivors with sequelae of neoplastic disease are more likely to lose their jobs than survivors without cancer stigma. Considering its social and economic impact, this intervention is implemented in the employment setting, specifically to protect against cancer stigma [20, 21]. While the right to oncological oblivion achieves anti-discrimination protection, it may inadvertently compromise health surveillance for workers exposed to occupational carcinogens. Indeed, despite the protection from discrimination that this law would afford to workers with past cancer histories, the law also has the potential to be detrimental to the health of these very workers: RTBF laws could have unintended health consequences, as workers with past cancer diagnoses may omit their medical history from occupational health assessments, potentially exposing themselves to greater risks if exposed to workplace carcinogens. This raises a critical question: in preventing discrimination, are we inadvertently undermining occupational health protection? The solution is clearly not to abrogate the right to oblivion but to establish precise mechanisms ensuring workers understand they may confidentially disclose cancer history to occupational physicians without employer knowledge. Some Key mechanisms could be proposed, such as standardised, confidential disclosure protocols across Member States; explicitly stating worker rights and physician obligations in an EU-wide guidance document; and improving information on this issue during health surveillance or professional training programs, in line with GDPR and national laws. Furthermore, during occupational physician training, it is crucial that professional education also focuses on balancing privacy rights with health assessment needs. Whilst respecting the right to be forgotten, workers must be reassured that sharing their medical history with the occupational physician can actually provide greater protection in the workplace, especially if they are exposed to occupational carcinogens. This is especially critical in preventive occupational health systems like Italy’s, where the occupational physician serves as guardian of all employee health data. The Italian case is paradigmatic: are we sufficiently confident that we are protecting our exposed workers who have been diagnosed with cancer, for whom the right to be forgotten exists? Current legislation is based simultaneously on protection against discrimination and exposure to carcinogens; in this way, the law would achieve the first objective, but could potentially compromise the second. This issue also involves all European countries with similar occupational health protection systems [22]. To date, there are some research gaps to consider regarding this topic, as there is a lack of longitudinal data on the rates of potential occupational cancers and other relevant health outcomes before and after the passage of oblivion laws. Although the study of different European regulatory approaches was explored in depth, legislative provisions and their application differ between Member States, limiting generalisability. Further studies are needed to investigate any variations in disclosure rates and health outcomes among cancer survivors exposed to occupational risks. Conclusion The right to oncological oblivion is a significant step forward in the fight against discrimination. However, this commentary highlights the ethical need to strike a balance between protecting cancer survivors from discrimination and ensuring adequate protection and occupational health surveillance for individuals exposed to carcinogens in the workplace. Rather than being adversarial, this balance should facilitate a harmonious relationship between the RTBF and health and safety in the workplace. The following policy questions could be discussed in the future: Should the EU develop standardised guidance on confidential disclosure protocols for occupational physicians?How can Member States strengthen the enforcement of confidentiality protections for cancer survivors?What health outcomes should be monitored, and what role should occupational health systems play in collecting data on these outcomes, after oblivion laws come into effect? Should the EU develop standardised guidance on confidential disclosure protocols for occupational physicians? Should the EU develop standardised guidance on confidential disclosure protocols for occupational physicians? How can Member States strengthen the enforcement of confidentiality protections for cancer survivors? How can Member States strengthen the enforcement of confidentiality protections for cancer survivors? What health outcomes should be monitored, and what role should occupational health systems play in collecting data on these outcomes, after oblivion laws come into effect? What health outcomes should be monitored, and what role should occupational health systems play in collecting data on these outcomes, after oblivion laws come into effect?